Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06858579 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Dianthus Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
480
Enrollment target
20
Study locations

NCT06858579 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Dianthus Therapeutics. The registered enrollment target is 480 participants, above the 117-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (310% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06858579, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Dianthus Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

Conditions Studied

Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • DRUG Placebo
  • DRUG DNTH103

Study Locations (20)

California

  • Clinical Study Site - Los Angeles
  • Clinical Study Site - San Francisco
  • Clinical Study Site - San Francisco

Arizona

  • Clinical Study Site - Phoenix
  • Clinical Study Site - Scottsdale

Florida

  • Clinical Study Site - Maitland
  • Clinical Study Site - Tampa

Illinois

  • Clinical Study Site - Chicago
  • Clinical Study Site - Edwardsville

New York

  • Clinical Study Site - New York
  • Clinical Study Site - New York

Alabama

  • Clinical Study Site - Birmingham

District of Columbia

  • Clinical Study Site - Washington D.C.

Hawaii

  • Clinical Study Site - Honolulu

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2025-02-10
Est. Completion 2030-12-31
Phase Phase 3

Sponsor

Dianthus Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06858579

The ClinicalTrials.gov registry entry for NCT06858579 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 117-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (310% higher). The listed sponsor is Dianthus Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06858579 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT06858579 about?

NCT06858579 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)". The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

What is the current status of trial NCT06858579?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-02-10. Estimated completion is 2030-12-31.

What conditions does trial NCT06858579 study?

This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.

What interventions are being tested in trial NCT06858579?

The interventions under investigation include: Placebo (DRUG), DNTH103 (DRUG).

Who is sponsoring clinical trial NCT06858579?

This trial is sponsored by Dianthus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06858579 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Inflammatory Demyelinating Polyneuropathy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.